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Background. This study investigated the usefulness of
ﬂuorine-18 ﬂuorodeoxyglucose-positron emission tomog-
raphy (FDG-PET) during the treatment of thymic epithe-
lial tumors in combination with Ki-67 evaluation based
on surgical cases in our department.
Methods. Between November 2003 and May 2011, 39
patients with thymic epithelial tumor underwent preop-
erative FDG-PET. The maximum standardized uptake
value (SUVmax) of each category within Masaoka stage,
World Health Organization classiﬁcation, tumor diame-
ter, myasthenia gravis, and Ki-67 label index were com-
pared. To examine risk factors for relapse, SUVmax, age,
sex, and surgical radicality were investigated in addition
to those items.
Results. The mean SUVmax was 4.5 (range, 1.2 to 14.6)
and was signiﬁcantly higher for Masaoka stage IV than
for I and II (all p < 0.008) and for World Health Organi-
zation classiﬁed thymic cancer compared with all other
types (all p < 0.0001). Mean SUVmax revealed signiﬁ-
cantly higher values for large tumors than for small
tumors (p  0.02). Mean SUVmax was signiﬁcantly
higher for high Ki-67–positive samples (p  0.0004),
indicating a strong correlation between SUVmax and the
Ki-67 label index (  0.77, p  0.0001). SUVmax accu-
rately reﬂected therapeutic efﬁcacy in patients with in-
duction therapy. Univariate analysis revealed Masaoka
stages III and IV and pathologically incomplete resection
as risk factors for relapse. On multivariate analysis,
independent risk factors for relapse comprised only
Masaoka stages III and IV.
Conclusions. FDG-PET SUVmax does reﬂect prolifera-
tion and invasiveness of thymic epithelial tumors and
can provide an index for diagnosis and treatment, al-
though it is not a risk factor for relapse. FDG-PET is also
useful for evaluating induction therapy efﬁcacy and
detecting relapse.
(Ann Thorac Surg 2013;95:305–11)
© 2013 by The Society of Thoracic Surgeons
For the management strategy of thymic epithelial tu-mors, not only morphologic ﬁndings but also bio-
logic features are important. Thymic epithelial tumors
usually can be assessed with computed tomography (CT)
and magnetic resonance imaging (MRI) [1, 2]. Morpho-
logic features are used for characterizing thymic lesions,
such as the contours and shapes of the lesions, the
presence of necrosis, calciﬁcation, mediastinal fat or
great vessel invasion, contrast enhancement, and adja-
cent lymph node enlargement. However, the morpho-
logic ﬁndings of thymic lesions have many degrees of
overlap among different entities, and thymic epithelial
tumors show a broad spectrum of biologic and morpho-
logic features [3, 4].
Fluorine-18 ﬂuorodeoxyglucose (18F-FDG) uptake on
positron emission tomography (PET) has been used to
discriminate between benign and malignant lesions in
various organs. FDG-PET has emerged as a powerful
diagnostic tool and is widely used for the diagnosis,
staging, and restaging of various neoplasms. Also, it has
been reported that FDG uptake on PET is correlated with
tumor aggressiveness as assessed by proliferative activity
and tumor invasiveness, particularly in lung tumors
[5, 6]. However, relatively few clinical studies with FDG-
PET have been conducted concerning thymic epithelial
tumors, and the usefulness of FDG-PET scans for pre-
dicting histologic types and the evaluation of tumor
aggressiveness of thymic epithelial tumors has not been
examined adequately.
Meanwhile, Ki-67 is a widely used marker of proliferation
and aggressiveness that has proven diagnostic and prog-
nostic relevance in various solid tumors. A few studies have
reported that the Ki-67 label index (LI) correlates with both
the histology and invasiveness of thymoma [7, 8].
Only a few studies have reported the usefulness of
FDG-PET in the management strategy of thymic epithe-
lial tumors. The present study used data from surgical
cases in our department to investigate the usefulness of
FDG-PET during the treatment of thymic epithelial tu-
mors combined with Ki-67 LI evaluation.
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The Kanazawa University Committee for Medical Ethics
approved this retrospective study. Individual consent
was obtained from the patients to use their resected
specimen for research.
Patients
This study included 39 patients with thymic epithelial
tumor who underwent preoperative FDG-PET. They
were treated at our institution between November 2003
and May 2011. All patients underwent chest CT and
FDG-PET preoperatively. Patients had to fast for 6 hours,
and FDG-PET was performed only if their serum glucose
level was less than 200 mg/dL. Each patient was injected
with 4.0 MBq/kg (0.11 mCi/kg) of 18F-FDG. After an
uptake of 60 minutes, patients were imaged using ECAT
ACCEL (Siemens, Munich, Germany) until June 2007,
and after that using a GE 4096 Plus PET whole body PET
scanner (GE Medical System, Milwaukee, WI), from the
base of the brain to the proximal thigh in 8 to 10 bed
positions (early phase), followed by a delayed scan of the
chest at 120 minutes (delayed phase). The maximum
standardized uptake value (SUVmax) of the thymic le-
sion was determined by drawing regions of interest on
the attenuation-corrected FDG-PET images around the
thymic lesion. SUVmax was calculated using the software
within the PET or PET-CT scanner and the following
formula: SUVmax  C (Ci/mL)/ID (Ci)/w (kg),
whereby C is the activity at a pixel within the tissue
deﬁned by a region of interest, ID is the injected dose,
and w is the patient’s body weight in kilograms. SUVmax
within the selected regions of interest was used exclu-
sively throughout this study.
This study compared the SUVmax of each category
within Masaoka stage, World Health Organization
(WHO) classiﬁcation, tumor diameter, presence or ab-
sence of myasthenia gravis (MG), and Ki-67 LI. Further-
more, to examine risk factors for relapse, Masaoka stage
(I/II as early stage or III/IV as advanced stage), WHO
classiﬁcation (A/AB/B1 as low-grade malignancy or B2/
B3/thymic cancer as high-grade malignancy), tumor di-
ameter ( median or  median), presence or absence of
MG, Ki-67 LI ( median or  median), SUVmax (
median or  median), age ( median or  median), sex,
and pathologically complete or incomplete resection
were also investigated. Disease-free interval (DFI) was
deﬁned as the time from the resection of the tumor until
relapse detected by CT or FDG-PET.
Ki-67 LI represents tumor cell proliferative activity and
was immunohistologically evaluated using resected thy-
mic epithelial tumor samples or preoperative biopsy
samples if induction therapy (IT) was conducted. Prolif-
erative activity was assessed immunohistochemically us-
ing the monoclonal antibody MIB1, which detects the
proliferation-associated antigen Ki-67. Mouse monoclo-
nal anti-human Ki-67 antigen (clone MIB1; Dako Corp,
Glostrup, Denmark) was diluted 100-fold, and immuno-
histochemical staining was performed. The hematoxylin
and eosin-stained slides of the tumor specimens were
reviewed, and blocks at the edge of the tumor area were
selected. Parafﬁn-embedded tumor tissues were cut into
4-m-thick sections and deparafﬁnized. Immunohisto-
chemical staining was performed using the labeled
streptavidin-biotin method, as previously described [9].
Ki-67 LI was scored as the ratio of MIB1-stained tumor
cells in which nuclear staining was positive [10, 11]. To
assess Ki-67 LI, all ﬁelds of the sections were scanned at
low (original magniﬁcation 40) and high (original mag-
niﬁcation 400) power, and the most strongly stained
areas were chosen. Evaluation of Ki-67 LI was performed
using anonymous prepared slides to avoid identiﬁcation
of the patients.
For the pathologic evaluation of the IT treatment efﬁ-
cacy, we categorized the pathologic response according
to the criterion of the General Rules of Clinical and Patho-
logical Records of Lung Cancer (7th Edition) of Japan [12]
which is based on the ratio of remaining viable cancer
cells to the total cancer cells in a resected specimen. The
criterion are Ef 0, no pathologic changes; Ef 1a, 2/3 and
above; Ef 1b, between 1/3 and 2/3; Ef 2, less than 1/3; Ef
3, 0. Two or more surgical pathologists reviewed the
pathologic response of IT.
Statistics
The mean  standard deviation values are shown, and
equality of means was analyzed with the unpaired t test.
Multiple comparisons of mean values between groups
were drawn using the Tukey honestly signiﬁcant differ-
ence test. The Pearson correlation test was used to
investigate the relationship between SUVmax and Ki-67
LI in thymic epithelial tumors. Disease-free survival
curves after resection of thymic epithelial tumors were
calculated using the Kaplan-Meier method and com-
pared using the log-rank test. Univariate and multivari-
ate Cox proportional hazards model was used to examine
the risk factors of relapse and to estimate hazard ratios
(HR) and conﬁdence interval (CI). Values of p of less than
.05 were considered signiﬁcant. Analyses were per-
formed with PASW Statistics 18 software (SPSS In.,
Chicago, IL).
Results
There were 16 men and 23 women, with a mean age of 55
years (range, 26 to 81 years). The mean maximum diam-
eter of thymic tumor was 61.5 mm (range, 20 to 137 mm).
The number of patients classiﬁed as Masaoka stages I, II,
III, or IV were 4, 22, 8, and 5, and those classiﬁed WHO
type A, AB, B1, B2, B3, or thymic cancer were 1, 4, 13, 11,
7 and 3, respectively. Eight patients were complicated by
MG, and 5 underwent IT. For IT, patients basically
received a uniﬁed multiagent chemotherapeutic regimen
including cisplatin and docetaxel. Three patients under-
went neoadjuvant chemotherapy plus concurrent radia-
tion at a dose of 40 Gy. Operative procedures comprised
extended thymothymectomy in 8 with combined resec-
tion of surrounding organs in 2, and thymothymectomy
resection in 31 with combined resection of surrounding
organs in 13. Complete resection was conﬁrmed in 34
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patients; however, 5 had pathologically incomplete
resection.
The operative-related mortality rate was 0%. Postoper-
ative complications included 1 patient each with postop-
erative crisis of MG, chylothorax, and pleural effusion.
Major cardiovascular, pulmonary, gastrointestinal, and
technical morbidity did not occur.
The mean follow-up after the initial operation of thy-
mic lesion was 40 months (range, 4 to 104; median, 58
months). All patients were monitored with periodic CT
and FDG-PET. Seven patients relapsed, and recurrent
lesion was conﬁrmed in all by FDG-PET conﬁrmed
recurrent lesion.
The mean SUVmax of the tumors in FDG-PET was 4.5
(range, 1.2 to 14.6; median, 3.9). Early and delayed SUVs
were measured in 10 patients, and mean SUVmax tended
to be higher in delayed images than in early images, at
5.9  4.6 and 4.9  3.9, respectively (p  0.62).
The mean value of each Masaoka stage and each type
of WHO classiﬁcation are shown in Figure 1. The
SUVmax of patients classiﬁed as Masaoka stages I, II, III, or
IV were 3.0  1.1, 3.6  1.4, 5.3  3.4, and 8.3  4.0 and
WHO types A, AB, B1, B2, B3, or thymic cancer were 2.3,
2.3  0.8, 3.7  1.5, 4.1  1.4, 4.9  1.5, and 12.1  3.2.
Mean SUVmax was signiﬁcantly higher for Masaoka
stage IV than for stages I and II (all p  0.008) and for
WHO classiﬁcation thymic cancer compared with all
other types (all p  0.0001). SUVmax tended to be higher
for advanced stage and higher malignant grade tumors.
Comparison of mean SUVmax between large (diame-
ter  median) and small (diameter  median) tumors
revealed signiﬁcantly higher values for large tumors,
5.6  3.3 and 3.5  1.8, respectively (p  0.02, Fig 2A).
Mean SUVmax tended to be higher in patients without
MG (absence, 4.9  3.0; presence, 3.0  0.9; p  0.09;
Fig 2B).
Positive staining for Ki-67 was set at 30% or higher
(median value), and mean SUVmax was signiﬁcantly
higher for positive samples (positive, 6.0  3.2; negative,
3.0  0.9; p  0.0004; Fig 3A), indicating a strong corre-
lation between SUVmax and Ki-67 LI (  0.77, p 
0.0001; Fig 3B).
The Ki-67 LI of patients classiﬁed as Masaoka stages I,
II, III, or IV were 0.20  0.09, 0.28  0.17, 0.36  0.18, and
0.54  0.30, and for WHO types A, AB, B1, B2, B3, or
thymic cancer were 0.16, 0.11  0.10, 0.25  0.15, 0.34 
0.13, 0.39 0.15, and 0.78 0.13, respectively. Mean Ki-67
LI tended to be higher for Masaoka stage IV than for
stages I (p  0.058) and II (p  0.056) and for WHO
classiﬁcation thymic cancer compared with all other
types (all p  0.004) and B3 compared with AB (p  0.04).
Fig 1. Box and whisker plots show compari-
son of mean maximum standardized uptake
value (SUVmax) of each category within (A)
Masaoka stage and (B) within the World
Health Organization (WHO) classiﬁcation.
For WHO classiﬁcation, SUVmax of thymic
cancer was higher compared with all other
types. The horizontal line in the middle of
each box indicates the median, the top and
bottom borders of the box mark the 75th and
25th percentiles, respectively, and the whis-
kers mark the 90th and 10th percentiles.
*p  0.008; **p  0.001; ***p  0.001 (signiﬁ-
cant difference).
Fig 2. Box and whisker plots show compari-
son of mean maximum standardized uptake
value (SUVmax) between (A) large (diameter
 median) and small (diameter  median)
tumors and between (B) patients with and
without myasthenia gravis. The horizontal
line in the middle of each box indicates the
median, the top and bottom borders of the box
mark the 75th and 25th percentiles, respec-
tively, and the whiskers mark the 90th and
10th percentiles. *p  0.02 (signiﬁcant differ-
ence). (N.S.  not signiﬁcant.)
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Ki-67 LI also tended to be higher for advanced-stage
tumors and those of higher malignant grade.
Table 1 reports the pathologic evaluation of treatment
efﬁcacy and changes of SUVmax between pre-IT and
post- IT in the 5 IT patients. SUVmax accurately reﬂected
therapeutic efﬁcacy, with increased treatment efﬁcacy on
pathologic evaluation associated with larger decreases in
mean SUVmax.
The univariate analysis showed Masaoka stages III and
IV (advanced stage) and pathologically incomplete resec-
tion were risk factors for relapse (Table 2). On multivar-
iate analysis, independent risk factors for relapse com-
prised only Masaoka stages III and IV (Table 3).
Comment
According to the results of this study, FDG-PET SUVmax
tended to be higher for advanced-stage tumors and those
at a higher malignant grade with a large amount of
epithelial components, especially in thymic cancer. In
addition, because a strong correlation between SUVmax
and Ki-67 LI was conﬁrmed, SUVmax was demonstrated
to reﬂect proliferation and invasiveness and can provide
an index for diagnosis and treatment. SUVmax is also
useful for evaluating IT efﬁcacy and detecting relapse;
thus, even if the thymic epithelial tumors do not shrink
after IT, the decision for a surgical or nonsurgical treat-
ment can be made based on FDG-PET ﬁndings. How-
ever, SUVmax is not a risk factor for relapse of thymic
epithelial tumors.
Thymic epithelial tumors are common primary neo-
plasms in the anterior mediastinum and are usually
slow-growing tumors, except for thymic cancer. How-
ever, they include variable histologic features and heter-
ogeneous oncologic behavior. Histologic features include
neoplastic epithelial cells with differing shapes and de-
grees of atypia and various degrees of nonneoplastic
lymphoid cells in the tumors. FDG-PET scanning is
performed to obtain further biologic information about
the lesions. Since Liu and colleagues [13] reported in the
ﬁrst study on the role of FDG-PET in the detection of
thymoma, only about a dozen publications to date have
reported FDG-PET imaging for thymic lesions.
Liu [4] reviewed these studies and summarized that
PET-CT is effective in differentiating thymic cancer from
other entities within the thymus and thymoma from
thymic hyperplasia, although the results for differentia-
tion between invasive and noninvasive thymomas may
be more equivocal. In those series, thymic cancer showed
a signiﬁcantly higher SUV than thymoma and thymic
hyperplasia [4, 14]. The previous reports indicated that
the classiﬁcation of thymomas by FDG-PET correlated
with the clinical Masaoka stage rather than the WHO
classiﬁcation, and a high SUV usually reﬂected invasive-
Fig 3. (A) Box and whisker plot shows com-
parison of mean maximum standardized up-
take value (SUVmax) between high Ki-67 la-
bel index ( median) and low Ki-67 label
index ( median). The horizontal line in the
middle of each box indicates the median, the
top and bottom borders of the box mark the
75th and 25th percentiles, respectively, and
the whiskers mark the 90th and 10th percen-
tiles. (B) Correlation is shown between SUV-
max and Ki-67 label index. *p  0.0004 (sig-
niﬁcant difference).





IT Effectsbc-Stage p-Stage Pre-IT Post-IT
1 IVa IVa B1 CR 7.5 1.5 Ef 1b
2 IIIc II B3 CR 5.5 0.5 Ef 2
3 IVa IVa B1 Chemotherapy 2.0 1.0 Ef 1a
4 IVb IVb B3 CR 7.5 2.3 Ef 1b
5 IIIc III B2 Chemotherapy 6.8 6.9 Ef 0
a IT effectiveness was evaluated by the ratio of remaining viable cancer cells in a resected specimen. b Ef 0, no pathologic changes; Ef 1a, 2/3 and
above; Ef 1b, between 1/3 and 2/3; Ef 2, less than 1/3. c Innominate vein invasion.
c-Stage  clinical Masaoka stage; CR  chemotherapy and radiotherapy; IT  induction therapy; p-Stage  pathological Masaoka
stage; SUVmax  maximum standardized uptake value; WHO  World Health Organization.
308 MATSUMOTO ET AL Ann Thorac Surg













ness of a malignant nature by the thymic tumor, whereas
a low SUV reﬂected a less invasive malignant thymoma
[15]. In contrast, Ito and colleagues [16] argued that the
low or high level of the SUV is a reﬂection of thymomas
of type B1 or of the combined types B1 plus B2, respec-
tively, and that the classiﬁcation of thymomas by FDG-
PET probably correlates not only with the clinical stage
but also with the WHO histologic subtype. Our results
showed that it is not possible to specify Masaoka stages
or the WHO histologic subtype with the absolute value of
SUVmax; however, advanced Masaoka stages and WHO
malignant grade subtypes had high SUVmax.
Our results showed a strong correlation between
SUVmax and Ki-67 LI. To our knowledge, this is the ﬁrst
report that demonstrates such relationship in thymic
epithelial tumors. Many studies have correlated Ki-67
expression with clinical outcome in malignant tumors. It
is clear that Ki-67 is of prognostic value for many types of
malignant tumors [17]. The effectiveness of using Ki-67
antibody as a tool to measure proliferative activity has
been widely investigated in a variety of tumors, however,
rarely in thymic epithelial tumors. The study by Luebke
and colleagues [17] using Ki-67 found that the Masaoka
staging system may be of prognostic relevance in thy-
moma type B3 and thymic cancer, and Ki-67 may indicate
the malignant potential of thymic carcinoma. As de-
scribed in our study, Ki-67 and SUVmax reﬂected prolif-
eration and invasiveness of thymic epithelial tumor;
however, the value did not correlate signiﬁcantly with
risk factors for relapse of the tumor. Independent risk
factors for relapse comprised only Masaoka stages III and
IV, as found in other studies [17, 18]. Kondo and col-
leagues [18] showed in a recent clinical study of 1,320
patients with thymic epithelial tumors that the Masaoka
clinical stage was an excellent predictor of the prognosis
of thymoma and thymic carcinoma, but not of thymic
carcinoid.
In the present study, we found that SUVmax accurately
reﬂected therapeutic efﬁcacy in the IT patients, with
increased treatment efﬁcacy on pathologic evaluation
associated with larger decreases in mean SUVmax. Mor-
phologic imaging cannot reliably distinguish a postoper-
ative scar or necrosis from a residual or recurrent tumor.
Response evaluation with morphologic imaging does not
correlate well with the pathologic response. The meta-
bolic response criteria seem to be more sensitive and
accurate. Kaira and colleagues [19] also reported that
PET-CT was useful in monitoring and predicting re-
sponse and outcome after treatment in unresectable
thymic epithelial tumors. In addition, we conﬁrmed re-
current lesions by FDG-PET in all relapsed patients.
Early detection and exact localization of tumor recur-
rence are important for the planning of further therapy.
Occasionally, CT scans cannot differentiate residual and
recurrent disease from ﬁbrosis and scar tissue, especially
when the disease is located in the anterior mediastinum
























Tumor diameter 0.791 (0.351–1.687) 0.538
60 mm 21
60 mm 18
Myasthenia gravis 0.716 (0.164–1.742) 0.506
Presence 8
Absence 31
Ki-67 label index 0.572 (0.216–1.234) 0.158
30% 20
30% 19
SUVmax 0.496 (0.187–1.072) 0.075
4.0 20
4.0 19
Age, years 0.768 (0.359–1.735) 0.499
60 25
60 14
Sex 0.764 (0.289–1.646) 0.506
Male 16
Female 23
Surgical radicality 0.353 (0.164–0.799) 0.015
Complete 34
Incomplete 5
CI  conﬁdence interval; HR  hazard ratio; SUVmax  maxi-
mum standardized uptake value; WHO  World Health
Organization.
Table 3. Multivariate Analysis of Risk Factors for Relapse
Factor Favorable Unfavorable HR (95% CI) p Value
Masaoka stage I and II III and IV 0.283 (0.062–0.795) 0.016
Surgical radicality Complete Incomplete 0.690 (0.295–1.612) 0.372
CI  conﬁdence interval; HR  hazard ratio.
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at a previous surgical site. FDG-PET is sensitive and
speciﬁc in diagnosing residual disease. Thus, PET is also
useful in the follow-up of patients who have undergone
thymic epithelial tumor excision when recurrence or
metastasis is suspected [16, 19, 20].
Some investigators reported the usefulness of FDG-
PET but have also observed a marked overlap in the
uptake of noninvasive and invasive thymomas [4, 14]. In
those reports, similarly to our results, SUVmax was
proportional to the size of the tumor. Small tumors are
not necessary noninvasive, however. We note that par-
tial-volume effects can cause a marked underestimation
of the true activity concentration within a tumor [21]. For
a spheric lesion with a diameter equivalent to 1.5 times
the spatial resolution of the PET scanner at full width half
maximum, the measured maximum activity concentra-
tion is only about 60% the true activity concentration. The
mean activity concentration is even lower, about 30% the
true activity concentration. Only when the diameter of
the lesion is about four times higher than the spatial
resolution of the scanner is the difference between the
measured peak activity concentration and the true activ-
ity concentration less than 5% [22]. The measured mean
activity concentration is still only approximately 60% the
true activity concentration [21].
Our analysis has some limitations. This study is a retro-
spective examination of a small series of patients with
thymic epithelial tumors surgically treated at a single insti-
tution. Although thymomas are included in the entity of
malignancy, they have varied degree of malignancy and
there are few relapses or metastases compared with cancer
due to their slow-growing behavior. Therefore, we could
not evaluate the effect of SUVmax on the prognosis of the
patients with thymic epithelial tumors because of short
follow-up periods. To clearly establish the utility of this
method, further studies with a greater number of patients
and long-term follow-up periods are needed. In addition, to
assess Ki-67 LI, limited areas with small amount of lympho-
cytes were scanned in WHO type B1 and B2 thymomas.
Because lymphocytes are easily stained by Ki-67, it is
difﬁcult to detect Ki-67 stained tumor cells in lymphocytes-
rich tumors.
In conclusion, PET SUVmax does reﬂect proliferation
and invasiveness of thymic epithelial tumor and can pro-
vide an index for diagnosis and treatment, although it is not
a risk factor for relapse. This value is also useful for
evaluating IT efﬁcacy and detecting relapse. Independent
risk factors for relapse comprised only Masaoka stages III
and IV.
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